Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France

References

• Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. Aids. 2012;26(1):45–56.
   PubMed Web of Science ®Google Scholar
• van Sighem A, Gras LA, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. Aids. 2010;24(10):1527–1535.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10.
   PubMed Web of Science ®Google Scholar
• Morlat P Prise en charge médicale des personnes vivant avec le VIH – Actualisation 2014 du Rapport 2013 – Sous la direction du Pr Phillipe Morlat et sous l’égide du CNS et de l’ANRS 2014 [ updated 2014]. [cited 2015 May 11]. Available from: http://www.sante.gouv.fr/IMG/pdf/experts-vih_actualisations2014.pdf
   Google Scholar
• Morlat P Prise en charge médicale des personnes vivant avec le VIH – recommandation du groupe d’experts – Sous la direction du Pr Phillipe Morlat et sous l’égide du CNS et de l’ANRS – Initiation d’un premier traitement antirétroviral 2017. [2017 Jun 2]. Available from: https://cns.sante.fr/wp-content/uploads/2017/01/experts-vih_initiation.pdf
   Google Scholar
• EPAR summary for the public – Triumeq: European Medicines Agency (EMA); [ updated 8 2014].
   Google Scholar
• Greig SL, Deeks ED. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015;75(5):503–514.
   PubMed Web of Science ®Google Scholar
• Pappa K, Granier C, Wynne B, et al. A phase III, randomized, double-blind study of the safety and efficacy of dolutegravir plus abacavir-lamivudine fixed-dose combination therapy administered QD compared to atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects. Brentford, UK: The ViiV Healthcare and the GlaxoSmithKline group of Companies. 2012.
   Google Scholar
• Wannamaker P, Brennan C, Harris J, et al. A phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naive adult subjects. Brentford, UK: ViiV Healthcare and the GlaxoSmithKline group of companies. 2013.
   Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–708.
   PubMed Web of Science ®Google Scholar
• Despiegel N, Anger D, Martin M, et al. Cost-effectiveness of dolutegravir in HIV-1 treatment-naive and treatment-experienced patients in Canada. Infect Dis Ther. 2015.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Marcelin AG, Despiegel N, et al. Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France. PLoS One. 2015;10(12):e0145885.
   PubMed Web of Science ®Google Scholar
• Patel DA, Snedecor SJ, Tang WY, et al., editors. 48-week efficacy of dolutegravir relative to commonly used 3rd agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. 14th European AIDS Conference; 2013 October 16-19; Brussels, Belgium.
   Google Scholar
• Patel DA, Snedecor SJ, Tang WY, et al. Efficacy and safety of dolutegravir relative to commonly-used 3rd-agents at 96 weeks in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. Melbourne, Australia: European AIDS Clinical Society (EACS). 2014.
   Google Scholar
• Rockstroh JK, DeJesus E, Saag M, et al., editors. Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-1 infected patients: final 5-year double-blind results from STARTMRK. XIX International AIDS Conference; 2012 July 22-27; Washington, DC.
   Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. Aids. 2009;23(17):2289–2300.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429–1441.
   PubMed Web of Science ®Google Scholar
• Kuhne FC, Chancellor J, Mollon P, et al. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clin Trials. 2010;11(2):80–99.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50(4):605–612.
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15(7):1045–1052.
   PubMed Web of Science ®Google Scholar
• Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J AcquirImmune Defic Syndr. 2010;55(5):558–564.
   PubMed Web of Science ®Google Scholar
• Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Aids. 2008;22(12):1389–1397.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49–58.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355–365.
   PubMed Web of Science ®Google Scholar
• Schapiro JM, Boucher CA, Kuritzkes DR, et al. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther. 2011;16(3):395–404.
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Aids. 2009;23(13):1679–1688.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49–59.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al., editors. Final 5-year results of the BENCHMRK studies: sustained antiretroviral effect of raltegravir, and exploratory analysis of late outcomes based on early virologic response. XIX International AIDS Conference; 2012 July 22-27; Washington, DC.
   Google Scholar
• Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. Aids. 2013;27:1771–1778.
   PubMed Web of Science ®Google Scholar
• Base des Médicaments et Informations Tarifaires: assurance Maladie - ameli.f; 2015 [updated 2015 Mar 19; cited 2015 Mar 19; cited 2015 Mar 19; cited 2015 Mar 19; cited 2015 Mar 30]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
   Google Scholar
• Biologie Médicale - Nomenclature des actes: Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés; 2014. [updated 9/2014; cited 2014 Oct 30]. Available from: http://www.codage.ext.cnamts.fr/f_mediam/fo/nabm/DOC.pdf
   Google Scholar
• Les tarifs conventionnels: assurance Maladie en ligne - ameli.fr; 2012 [updated 2012 jun 21; cited 2012 21; cited 2014 jun 21; cited 2014 Oct 21; cited 2014 Oct 30]. Available from: http://www.ameli.fr/professionnels-de-sante/infirmiers/votre-convention/les-tarifs-conventionnels.php
   Google Scholar
• Les tarifs conventionnels - Tarifs applicables aux pharmaciens biologistes: assurance Maladie en ligne - ameli.fr; 2011 [updated 2011 Dec 6; cited 2011 Dec 6; cited 2014 Dec 6; cited 2014 Oct 6; cited 2014 Oct 30]. Available from: http://www.ameli.fr/professionnels-de-sante/directeurs-de-laboratoires-d-analyses-medicales/votre-convention/les-tarifs-conventionnels.php
   Google Scholar
• Remboursement d’une consultation médicale - Consultation du médecin correspondant (pour un suivi régulier - Spécialiste secteur 1 ou secteur 2 avec option de coordination: service-Public.fr; 2014 [updated 2014 Oct 8; cited 2014 Oct 8; cited 2014 Oct 8; cited 2014 Oct 8; cited 2014 Oct 30]. Available from: http://vosdroits.service-public.fr/particuliers/F1069.xhtml#N101BF
   Google Scholar
• Paltiel AD, Scharfstein JA, Seage GR III, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998;18(2 Suppl):S93–105.
   PubMed Web of Science ®Google Scholar
• Parrondo J, Moreno S, Losa JE, et al. Cost-utility analysis of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) as a single tablet treatment of naive HIV infected patientss. Value Health. 2015;18(7):A588–9.
   PubMed Web of Science ®Google Scholar
• Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States. Value Health. 2011;14(5):657–664.
   PubMed Web of Science ®Google Scholar
• Juday T, Correll T, Bentley T. et al. editors. Cost-effectiveness of elvitegravir/cobicistat/emtricitabine/tenofovir compared with efavirenz/emtricitabine/tenofovir as first-line HIV antiretroviral therapy in the US adult population. International Society for Pharmacoecnomics and Outcomes Research: New orleans, LA. 2013 May 18-22.
   Google Scholar
• Tilden D, Jackson D, LeReun C, et al., editors. A modelled economic evaluation of raltegravir compared to standard practice in Australia for treatment naive patients with HIV. International Society for Pharmacoeconomics and Outcomes Research, 4th Asia Pacific Conference; 2010 September 5-7; Phuket, Thailand.
   Google Scholar
• Chaudhary MA, Elbasha EH, Kumar RN, et al. Cost-effectiveness of raltegravir in HIV/AIDS. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):627–639.
   PubMed Web of Science ®Google Scholar
• Girod I, Bell M, Adriaenssen I, et al., editors. Cost-effectiveness of rilpivirine- or efavirenz-based regimens for treatment-naive, HIV-1-infected patients: NHS England perspective. 18th Annual Conference of the British HIV Association; 2012; Birmingham, UK.
   Google Scholar
• Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84–92.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Brogan AJ, Talbird SE, et al. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. Aids. 2012;26:355–364.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
   PubMed Web of Science ®Google Scholar
• Padilla M, Gonzalez-Cordon A, Rojas J, et al. Tolerability of integrase inhibitors in a real-life setting. International workshop on comorbidities and adverse drug reations in HIV. New York, NY: Antiviral Therapy; 2016. A28.
   Google Scholar
• Lepik KJ, Nohpal B, Toy KJ, et al. Adverse drug reactions associated with integrase stand transfer inhibitors (INSTI) in clinical practice: post-marketing experience with raltegravir, elvitegravir-cobicistat and dolutegravir. Abstract TUPEB256. 8th International AIDS Society Conference; 2015 July 19–22; Vancouver, Canada.
   Google Scholar
• Hsu R Abstract 664. Conference on Retroviruses and Opportunistic Infections; 2017 February 13-16; Seattle, WA.
   Google Scholar
• Llibre JM Poster 651. Conference on Retroviruses and Opportunistic Infections; 2017 February 13-16; Seattle, WA.
   Google Scholar
• Baldin G, Borghetti A, Capetti A, et al. A comparison between tenofovir/emtricitabine/elvitegravir/cobicistat and dolutegravir-based three-drug regimens as switch strategies for virologically controlled, HIV-infected patients. Poster P106. HIV; 2016 October 23-26; Glasgow, United Kingdom.
   Google Scholar
• Madeddu G, Ricci E, Gulminetti R, et al. Dolutegravir tolerability in clinical practice: results from the SCOLTA cohort. Poster P230. HIV; 2016 October 23-26; Glasgow, United Kingdom.
   Google Scholar
• Postel N, Mueller M, Wyen C, et al. The DOL-ART cohort: providing evidence from real-world data – use of dolutegravir-based regimens in routine clinical care in Germany. Poster P133. HIV; 2016 October 23-26; Glasgow, United Kingdom.
   Google Scholar
• Tau L, Ziv-Baran T, Cohen-Poradosu R, et al. Switch to dolutegravir in HIV patients responding to a first-line antiretroviral treatment: 48 weeks results. Poster P108. HIV; 2016 October 23-26; Glasgow, United Kingdom.
   Google Scholar
• Capetti AF, Sterrantino G, Cossu MV, et al. Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS One. 2016;11(10):e0164753.
   PubMed Web of Science ®Google Scholar
• Morales A, Pérez C, Díaz A, et al. Dolutegravir discontinuation in real life. Abstract PT023. ESCP-NSF SYMPOSIUM; 2016 October 5-7; Oslo, Norway.
   Google Scholar
• Waqas S, O’Connor M, Levey C, et al. Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland. SAGE Open Med. 2016;4:2050312116675813.
   Google Scholar
• Ferrer E Poster 275. Australasian HIV & AIDS Conference; 2016 November 16-18; Adelaide, Australia.
   Google Scholar
• Vivancos-Gallego M, Moreno A, Perez-Elias M, et al. Discontinuation of dolutegravir (DTG)-based regimens in clinical practice. Poster P116. HIV; 2016 October 23-26; Glasgow, United Kingdom.
   Google Scholar
• Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. Aids. 2015;29(2):167–174.
   PubMed Web of Science ®Google Scholar